FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies.

Results from a drug trial showed AstraZeneca and Amgen's new drug Tezspire significantly reduced nasal polyp severity, the need for surgery and anti-inflammatory steroid use in patients with ...

Wellinks has joined forces with Careabout Health to introduce its virtual COPD management program to the New Jersey and ...

However, the medication's modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain. The new drug will also carry a list price of $15.50 per ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

[39,40,41,42,43,44,45] Significant differences in health beliefs, experiences, and behaviors were observed between COPD patients with high medication adherence and suboptimal adherence. The ...

These researchers found that the new classification thresholds affect severity classification in the same proportion for White and Black patients with COPD and are appropriately associated with ...